Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. … Read more
Syndax Pharmaceuticals Inc (SNDX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.611x
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has a cash flow conversion efficiency ratio of -0.611x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-70.53 Million) by net assets ($115.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Syndax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Syndax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Syndax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ipsos SA
OTCGREY:IPSOF
|
0.077x |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
-0.098x |
|
Hisense Kelon Electrical Holdings Co Ltd
SHE:000921
|
0.104x |
|
iQIYI Inc
NASDAQ:IQ
|
-0.020x |
|
Sinomach Precision Industry Co Ltd
SHE:002046
|
-0.034x |
|
CCC S.A.
WAR:CCC
|
0.290x |
|
Wuxi Autowell Technology Co Ltd
SHG:688516
|
0.021x |
|
Burckhardt Compression
SW:BCHN
|
0.100x |
Annual Cash Flow Conversion Efficiency for Syndax Pharmaceuticals Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $288.12 Million | $-274.90 Million | -0.954x | -229.24% |
| 2023-12-31 | $554.20 Million | $-160.60 Million | -0.290x | -1.34% |
| 2022-12-31 | $467.45 Million | $-133.68 Million | -0.286x | -500.88% |
| 2021-12-31 | $408.37 Million | $29.13 Million | 0.071x | +125.25% |
| 2020-12-31 | $252.19 Million | $-71.26 Million | -0.283x | +82.36% |
| 2019-12-31 | $31.60 Million | $-50.61 Million | -1.602x | -23.98% |
| 2018-12-31 | $53.05 Million | $-68.53 Million | -1.292x | -184.50% |
| 2017-12-31 | $104.32 Million | $-47.37 Million | -0.454x | -8.68% |
| 2016-12-31 | $84.14 Million | $-35.16 Million | -0.418x | -1047.83% |
| 2015-12-31 | $66.70 Million | $-2.43 Million | -0.036x | -101.45% |
| 2014-12-31 | $-5.72 Million | $-14.39 Million | 2.518x | +508.99% |
| 2013-12-31 | $11.85 Million | $-7.29 Million | -0.616x | -294.22% |
| 2012-12-31 | $-29.29 Million | $-9.28 Million | 0.317x | -39.73% |
| 2011-12-31 | $-19.05 Million | $-10.02 Million | 0.526x | -- |